StockData

Haoxi Health Technology vs Stran &

HAO and SWAG side by side, both in business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HAO and SWAG compare

Haoxi Health Technology grew revenue faster over the last twelve months (67.1% versus 10.3% for Stran &).

Stran & keeps more of each dollar of sales as profit, with a net margin of 0.05% compared with −17.4% at Haoxi Health Technology.

Stran & scores higher on the StockData Score (11 against 4 for Haoxi Health Technology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHAOSWAG
Size and price
Market cap–$21.6M
Share price$2.00$1.16
Change, 1 year−99.9%−58.1%
Change, 5 years–−62.9%
Beta (5Y)1.750.57
Employees30154
StockData Score
Total score411 (better)
Valuation score01 (better)
Growth score22
Performance score03 (better)
Health score25 (better)
Dividend score00
Valuation
P/S–0.2×
P/B–0.7×
EV/EBITDA–106×
FCF yield–−19.9%
Fair value–$0.877
Margin of safety–−32.3%
Growth
Revenue growth (TTM)67.1% (better)10.3%
Revenue growth, 5Y average–25.2%
Net income growth (TTM)−346%–
EPS growth (TTM)−111%–
Profitability
Gross margin1.1%29.7% (better)
Operating margin−17.6%−0.91% (better)
Net margin−17.4%0.05% (better)
FCF margin–−3.6%
Return on equity−54.1%0.18% (better)
Return on invested capital−79.5%−3.3% (better)
Financial health
Debt / equity0.09 (better)0.00
Interest coverage−184.3×–
Current ratio4.53 (better)1.96
Altman Z-score–2.88
Piotroski F-score35 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–12.8%
Held by insiders–52.6%
Insider net buying, 12 months$800K–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.